Get the Stockscreener App
221.09
2.43%
5.25
After Hours:
221.00
-0.09
-0.04%
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $221.09, with a volume of 4.63M.
It is up +2.43% in the last 24 hours and up +1.02% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$215.84
Open:
$215.1
24h Volume:
4.63M
Relative Volume:
1.02
Market Cap:
$155.42B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
42.73
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
+5.60%
1M Performance:
+1.02%
6M Performance:
+16.76%
1Y Performance:
+16.08%
1-Day Range:
$214.28
$222.42
1-Week Range:
$206.68
$222.42
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
221.09 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
658.52 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
390.90 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.26 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.09 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher Corp. stock holds near USD 200 as investors eye earnings and guidance - ad-hoc-news.de
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
UBS assumes coverage on Danaher stock with buy rating, $250 target - Investing.com Nigeria
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says - Yahoo Finance
Danaher Corp. stock gains support from UBS buy rating and July earnings beat - ad-hoc-news.de
Danaher (DHR) Stock Forecast and Price Target 2026 $DHR - MarketBeat
Danaher stock heads into the open after a 0.87 percent slip - ad-hoc-news.de
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher stock holds near $207 after Q2 beat - ad-hoc-news.de
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Danaher stock heads into the open after a 0.5 percent dip - ad-hoc-news.de
Danaher Corp stock edges lower as investors weigh latest analyst targets and dividend signal - ad-hoc-news.de
Danaher (NYSE:DHR): Is Its Next Move Tied to Inflation Data? - Kalkine Media
Danaher stock holds after Q2 revenue and EPS beat - AD HOC NEWS
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Danaher Corp. stock trades near 52-week highs as investors digest recent earnings - AD HOC NEWS
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Danaher (DHR) Seen Deftly Navigating AI Integration - Yahoo Finance
Baird Adjusts Price Target on Danaher to $238 From $232, Keeps Outperform Rating - marketscreener.com
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium - Yahoo Finance
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Corp. stock holds steady after recent pullback as investors weigh Q2 2026 results - AD HOC NEWS
Danaher (DHR) Stock Looks Fairly Valued On Cash Flow Yet Overvalued On Earnings - simplywall.st
A Look at Danaher Corp (DHR) After 3.1% Decline -- GF Value $242 - GuruFocus
Danaher Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Danaher Corp Stock (DHR) Moved Down by 3.06% on Sep 1: Facts Behind the Movement - TradingKey
HSBC Adjusts Price Target on Danaher to $250 From $230, Maintains Buy Rating - marketscreener.com
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
Is Danaher Stock Underperforming the Nasdaq? - Barchart.com
Why Danaher (DHR) Remains a Healthcare Compounder to Watch - Yahoo Finance
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain? - Eastern Progress
Danaher president & CEO Rainer Blair sells $12.7 million in company stock - investing.com
Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside? - Yahoo Finance
Danaher (NYSE: DHR) holder Blair plans $12.7M stock sale - Stock Titan
Resilient Danaher stock edges higher as institutional buying and analyst support frame the outlook - Ad-hoc-news.de
U.S. Market Edge Lower— Danaher Corporation's Bullish Breakout in Focus - kalkine.ca
6,796 Shares in Danaher Corporation $DHR Bought by Portfolio Design Labs LLC - MarketBeat
17 CAPITAL PARTNERS, LLC's Danaher Corp(DHR) Holding History - GuruFocus
10,799 Shares in Danaher Corporation $DHR Acquired by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Somerville Kurt F Purchases Shares of 45,245 Danaher Corporation $DHR - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Makes New Investment in Danaher Corporation $DHR - MarketBeat
932,220 Shares in Danaher Corporation $DHR Bought by Bank of New York Mellon Corp - MarketBeat
Bank of New York Mellon Corp Purchases New Position in Danaher Corporation $DHR - MarketBeat
Danaher Corporation (NYSE:DHR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher (NYSE:DHR) Valuation Debate Deepens After Life Sciences Progress - Kalkine Media
Integrated DNA Technologies Defines the Next Era of DNA Synthesis: Full-Spectrum Capabilities for Speed, Complexity and Scale - StreetInsider
Madison Asset Management LLC Acquires Shares of 448,611 Danaher Corporation $DHR - MarketBeat
Puzo Michael J Makes New Investment in Danaher Corporation $DHR - MarketBeat
Kentucky Farm Bureau Mutual Insurance Co Buys New Position in Danaher Corporation $DHR - MarketBeat
Tocqueville Asset Management L.P. Purchases Shares of 59,318 Danaher Corporation $DHR - MarketBeat
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
5.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):